Nevro Corp. (NYSE:NVRO) today closed its initial public offering, saying it raised $144.9 million by offering 8.05 million shares at $18 apiece.
Neuromodulation/Neurostimulation
Nevro boosts IPO to $126m
Nevro Corp. today raised the stakes on its forthcoming initial public offering, saying it will offer half a million more shares at a dollar over the high end of its prior range.
Nevro sets range for IPO of up to $106m
Nevro Corp. set the price range for its forthcoming initial public offering, which would raise $106.3 million at the high end of the range.
Menlo Park, Calif.-based Nevro plans to trade on the NASDAQ exchange under the symbol NVRO, according to a regulatory filing.
Report: EndoStim tables IPO
EndoStim, citing poor market conditions, has tabled its initial public offering it hoped would raise nearly $36 million for its neurostimulation device for gastroesophageal reflux disease, according to Renaissance Capital.
EndoStim had planned to put $10 million of the IPO’s proceeds into clinical studies and another $14 million to commercialize the system.
Boston Scientific wins CE Mark, FDA nod for spinal surgical leads
Sensory Medical raises $1.4m for Relaxis restless legs treatment
Sensory Medical shook a leg on a 2nd tranche of funding since receiving FDA clearance last spring for its device to relieve symptoms of restless legs syndrome, reporting $1.4 million in fresh funding on the heels of a $1 million tranche in June.
Medtronic launches Verify incontinence device in the U.S.
Nevro registers $100m IPO
Nevro Corp. said it plans to raise more than $100 million in an initial public offering of stock for its implantable spinal cord stimulation system to treat chronic pain.
UCLA spinout NeuroSigma seeks $50m in IPO
NeuroSigma aims to reap as much as $50.2 million in its upcoming initial public offering for the UCLA spinout’s noninvasive system to treat drug-resistant epilepsy.
NeuroSigma plans to sell 3.6 million shares on the NASDAQ exchange for between $13 and $15 each, reserving the symbol NSIG, according to a regulatory filing.
Funding: InSightec raises $12.5M from Chinese backers
Israeli device maker InSightec added $12.5 million to its coffers thanks to the support of Chinese backers, the firm’s parent company announced.